Recombinant human interleukin-6 infusion during low-intensity exercise does not enhance whole body lipolysis or fat oxidation in humans

American Journal of Physiology - Endocrinology and Metabolism

Volumn 289, Issue 1 52-1, 2005, Pages

  Hiscock, N ^a,b,c   Fischer, C P ^a   Sacchetti, M ^a   Van Hall, G ^a   Febbraio, M A ^b   Pedersen, B K ^a  

^a Rigshospitalet   (Denmark)

^b RMIT UNIVERSITY   (Australia)

^c UNILEVER RESEARCH   (United Kingdom)

Author keywords

Cytokine; Metabolism

Indexed keywords

INTERLEUKIN 6; PALMITIC ACID;

ADULT; ARTICLE; BICYCLE ERGOMETER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EXERCISE; FATTY ACID METABOLISM; HUMAN; LIPOLYSIS; LOW DRUG DOSE; MALE; MATHEMATICAL ANALYSIS; OXIDATION; OXYGEN CONSUMPTION; PRIORITY JOURNAL; TRAINING;

ADULT; EXERTION; FATTY ACIDS; HUMANS; INFUSIONS, INTRA-ARTERIAL; INTERLEUKIN-6; LIPOLYSIS; MALE; OXYGEN; OXYGEN CONSUMPTION; RECOMBINANT PROTEINS;

EID: 21044442882     PISSN: 01931849     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpendo.00274.2004     Document Type: Article

References (27)

1. Akira S, Taga T, and Kishimoto T. Interleukin-6 in biology and medicine. Adv Immunol 54: 1-78, 1993.
2. Divertie GD, Jensen MD, Cryer PE, and Miles JM. Lipolytic responsiveness to epinephrine in nondiabetic and diabetic humans. Am J Physiol Endocrinol Metab 272: E1130-E1135, 1997.
3. Djurhuus CB, Gravholt CH, Nielsen S, Pedersen SB, Moller N, and Schmitz O. Additive effects of cortisol and growth hormone on regional and systemic lipolysis in humans. Am J Physiol Endocrinol Metab 286: E488-E494, 2004.
4. Febbraio MA and Pedersen BK. Muscle-derived interleukin-6: mechanisms for activation and possible biological roles. FASEB J 16: 1335-1347, 2004.
5. Hiscock N, Chan S, Bisucci T, Darby I, and Febbraio MA. Skeletal myocytes are a source of interleukin-6 mRNA expression and protein release during contraction: evidence of fiber type specificity. FASEB J 18: 992-994, 2004.
6. Holmes AG, Watt MJ, and Febbraio MA. Suppressing lipolysis increases interleukin-6 at rest and during prolonged moderate-intensity exercise in humans. J Appl Physiol 97: 689-696, 2004.
7. Horber FF, Marsh HM, and Haymond MW. Differential effects of prednisone and growth hormone on fuel metabolism and insulin antagonism in humans. Diabetes 40: 141-149, 1991.
8. Jensen MD. Cytokine regulation of lipolysis in humans? J Clin Endocrinol Metab 88: 3003-3004, 2003.
9. Jensen MD. Fate of fatty acids at rest and during exercise: regulatory mechanisms. Acta Physiol Scand 178: 385-390, 2003.
10. Lyngso D, Simonsen L, and Bulow J. Metabolic effects of interleukin-6 in human splanchnic and adipose tissue. J Physiol 543: 379-386, 2002.
11. Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS, Klein S, and Coppack SW. Subcutaneous adipose tissue releases interleukin-6, but not tumour necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 82: 4196-4200, 1997.
12. Møller N, Jørgensen JOL, Schmitz O, Møller J, Christiansen JS, Alberti KGMM, and Ørskov H. Effects of a growth hormone pulse on total and forearm substrate fluxes in humans. Am J Physiol Endocrinol Metab 258: E86-E91, 1990.
13. Ostrowski K, Rohde T, Zacho M, Asp S, and Pedersen BK. Evidence that interleukin-6 is produced in human skeletal muscle during prolonged running. J Physiol 508: 949-953, 1998.
14. Ottosson M, Lonnroth P, Bjorntorp P, and Eden S. Effects of cortisol and growth hormone on lipolysis in human adipose tissue. J Clin Endocrinol Metab 85: 799-803, 2000.
15. Penkowa M, Keller C, Keller P, Jauffred S, and Pedersen BK. Immunohistochemical detection of interleukin-6 in human skeletal muscle fibers following exercise. FASEB J 17: 2166-2168, 2003.
16. 15a. Petersen EW, Carey AL, Sacchetti M, Steinberg GR, Macaulay SL, Febbraio MA, and Pedersen BK. Acute IL-6 treatment increases fatty acid turnover in elderly humans in vivo and in tissue culture in vitro. Am J Physiol Endocrinol Metab 288: E155-E162, 2005.
17. Spath-Schwalbe E, Hansen K, Schmidt F, Schrezenmeier H, Marshall L, Burger K, Fehm HL, and Born J. Acute effects of recombinant human interleukin-6 on endocrine and central nervous sleep functions in healthy men. J Clin Endocrinol Metab 83: 1573-1579, 1998.
18. Starkie RL, Rolland J, Angus DJ, Anderson MJ, and Febbraio MA. Circulating monocytes are not the source of elevations in plasma IL-6 and TNF-α levels after prolonged running. Am J Physiol Cell Physiol 280: C769-C774, 2001.
19. Steele R. Influences of glucose loading and of injected insulin on hepatic glucose output. Ann NY Acad Sci 82: 420-430, 1959.
20. Steensberg A, van Hall G, Osada T, Sacchetti M, Saltin B, and Pedersen BK. Production of IL-6 in contracting human skeletal muscle can account for the exercise-induced increase in plasma IL-6. J Physiol 529: 237-242, 2000.
21. Stouthard JM, Romijn JA, van der Poll T, Endert E, Klein S, Bakker PJ, Veenhof CH, and Sauerwein HP. Endocrinologic and metabolic effects of interleukin-6 in humans. Am J Physiol Endocrinol Metab 268: E813-E819, 1995.
22. Tsigos C, Papanicolaou DA, Defensor R, Mitsiadis CS, Kyrou I, and Chrousos GP. Dose effects of recombinant human interleukin-6 on pituitary hormone secretion and energy expenditure. Neuroendocrinology 66: 54-62, 1997.
23. Van Hall G, Sacchetti M, Radegran G, and Saltin B. Human skeletal muscle fatty acid and glycerol metabolism during rest, exercise and recovery. J Physiol 543: 1047-1058, 2002.
24. Van Hall G, Steensberg A, Sacchetti M, Fischer C, Keller C, Scherling P, Hiscock N, Moller K, Saltin B, Febbraio MA, and Pedersen BK. Interleukin-6 stimulates lipolysis and fat oxidation in humans. J Clin Endocrinol Metab 88: 3005-3010, 2003.
25. Wallenius V, Wallenius K, Ahren B, Rudling M, Carlsten H, Dickson SL, Ohlsson C, and Jansson JO. Interleukin-6-deficient mice develop mature-onset obesity. Nat Med 8: 75-79, 2002.
26. Wallenius K, Wallenius V, Sunter D, Dickson SL, and Jansson JO. Intracerebroventricular interleukin-6 treatment decreases body fat in rats. Biochem Biophys Res Commun 293: 560-565, 2002.
27. Wolfe RR. Stable isotope approaches for study of energy substrate metabolism. Fed Proc 41: 2692-2697, 1982.